DGKE and methylmalonic aciduria and homocystinuria type cblC: Eculizumab’s efficacy is generally not reliant on genetic mutations, as both patients with and without complement gene abnormalities can respond similarly, except in cases involving cobalamin C deficiency or DGKE mutations [37].